Our Pricing

Understanding Wegovy Dosing: When Weight Loss Begins

Many patients ask at what dose does Wegovy start working UK prescribers recommend, and the clinical answer is nuanced. Most patients notice initial appetite suppression during the 0.5mg to 1mg escalation phase, but the full therapeutic effect emerges at the maintenance dose of 2.4mg weekly. At Cured Pharmacy, our UK-registered clinical team guides you through the complete titration schedule with transparent pricing from £79.00 and discreet delivery.

At What Dose Does Wegovy Start Working? The Clinical Evidence

Wegovy (semaglutide 2.4mg) follows a structured dose escalation protocol licensed by the MHRA. The titration begins at 0.25mg weekly for four weeks, then increases every four weeks through 0.5mg, 1mg, and 1.7mg before reaching the maintenance dose of 2.4mg at week 17 [1]. This gradual escalation minimises gastrointestinal side effects whilst allowing your body to adapt to the medication's metabolic effects.

Clinical data from the STEP 1 trial demonstrates that patients begin experiencing measurable weight loss during the early titration phases, with average reductions of 2-3% body weight by week 8 (during the 0.5mg-1mg doses) [1]. However, the most significant weight loss occurs after reaching the 2.4mg maintenance dose, with participants achieving an average 14.9% total body weight reduction over 68 weeks [1].

The mechanism behind this dose-dependent response relates to semaglutide's action on GLP-1 receptors in the brain and gastrointestinal tract. Lower doses provide modest appetite suppression and delayed gastric emptying, whilst the full 2.4mg dose produces sustained activation of satiety pathways and significant reductions in energy intake [2]. Most patients report noticeable appetite changes within 2-4 weeks of starting treatment, even at the initial 0.25mg dose, though weight loss typically becomes evident from week 4-8 onwards.

The Wegovy Titration Schedule: Week-by-Week Dosing

Understanding the complete Wegovy dosing schedule UK prescribers follow helps set realistic expectations for your weight loss journey. The structured titration spans 16 weeks before you reach the therapeutic maintenance dose, and each escalation serves a specific clinical purpose beyond simply reducing side effects.

Weeks 1-4 begin with 0.25mg subcutaneous injections once weekly. During this phase, you're introducing your body to GLP-1 receptor activation, and many patients notice reduced cravings and smaller portion sizes. Weeks 5-8 increase to 0.5mg weekly, where appetite suppression becomes more pronounced and early weight loss typically begins. Weeks 9-12 progress to 1mg weekly, the dose at which most patients experience consistent weekly weight reduction. Weeks 13-16 use 1.7mg weekly as the penultimate step, preparing your metabolism for the full therapeutic dose. From week 17 onwards, you maintain 2.4mg weekly indefinitely, subject to ongoing prescriber review [1].

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) emphasises that patients should not skip titration steps or accelerate the schedule without prescriber approval. The graduated approach reduces the incidence of nausea, vomiting, and diarrhoea from approximately 44% (when starting at higher doses) to under 20% when following the licensed protocol [2]. If you experience persistent side effects at any dose, your UK prescriber may extend that phase by an additional four weeks before escalating further.

What Happens If You Miss a Dose During Titration?

If you miss a Wegovy injection and it's been less than 5 days since your scheduled dose, administer it as soon as you remember. If more than 5 days have passed, skip that dose entirely and resume your regular schedule with the next injection [3]. During titration, missing doses may delay your progression to higher strengths, and your prescriber may recommend repeating the current dose level for an additional week to maintain therapeutic consistency.

Wegovy Dose Response: Weight Loss Results by Strength

The relationship between Wegovy dose and weight loss follows a clear dose-response curve documented across the STEP clinical trial programme. In STEP 1, participants who reached and maintained the 2.4mg dose lost significantly more weight than those on lower maintenance doses, demonstrating that the full therapeutic effect requires the complete titration [1].

At the 0.5mg and 1mg doses (weeks 5-12 of treatment), average weight loss ranges from 5-8% of baseline body weight in clinical practice, though individual responses vary considerably [1]. These intermediate doses produce meaningful metabolic benefits including improved glycaemic control and reduced cardiovascular risk markers, but they represent transitional phases rather than optimal therapeutic endpoints. The 1.7mg dose (weeks 13-16) typically yields 10-12% weight reduction, approaching but not matching the full maintenance dose efficacy.

The 2.4mg maintenance dose produces the maximum licensed effect, with STEP 1 participants losing an average 14.9% body weight over 68 weeks compared to 2.4% with placebo [1]. Approximately 50% of patients achieved at least 15% weight loss, and 32% lost 20% or more of their starting weight [1]. These results position Wegovy as one of the most effective pharmacological weight management options currently licensed in the UK by the MHRA.

Individual Variation in Dose Response

Not all patients require the full 2.4mg dose to achieve their clinical goals. Some individuals experience substantial weight loss and appetite control at 1mg or 1.7mg, and UK prescribers may consider maintaining these lower doses if you've reached your target weight and are experiencing side effects at higher strengths. Conversely, a small percentage of patients show minimal response even at 2.4mg, and your prescriber may discuss alternative treatments or adjunctive lifestyle interventions during your follow-up consultations.

When Does Wegovy Start Working? Timeline of Effects

The question of when Wegovy starts working depends on which effects you're measuring. Appetite suppression and reduced food cravings typically emerge within the first 1-2 weeks of treatment, even at the initial 0.25mg dose, as semaglutide begins modulating GLP-1 receptors in the hypothalamus and brainstem [2]. These neurological effects occur rapidly, though the magnitude increases with each dose escalation.

Measurable weight loss on the scales usually becomes apparent from week 4-8 onwards, corresponding to the 0.5mg-1mg dose range. In the STEP trials, the median time to 5% weight loss was approximately 12 weeks, whilst 10% weight loss occurred at a median of 24 weeks [1]. Maximum weight loss typically occurs between months 9-12 of continuous treatment at the 2.4mg maintenance dose, after which weight stabilises if you maintain the medication and lifestyle modifications.

Metabolic improvements such as reduced HbA1c, improved lipid profiles, and decreased blood pressure often precede visible weight loss and can be detected as early as week 8-12 in patients with baseline metabolic dysfunction [4]. These cardiovascular and glycaemic benefits contribute to the overall health improvements beyond cosmetic weight reduction, which is why NICE guidelines support semaglutide use in weight management for patients with obesity-related comorbidities.

Factors That Influence Wegovy Effectiveness at Each Dose

Several patient-specific variables affect how quickly and effectively Wegovy works at each dose level. Baseline body mass index plays a significant role—patients with higher starting BMIs often experience greater absolute weight loss but may require the full 2.4mg dose to achieve comparable percentage reductions [1]. Conversely, individuals closer to the lower BMI threshold (30 kg/m² for obesity, or 27 kg/m² with comorbidities) may respond well to intermediate doses.

Adherence to the injection schedule critically determines outcomes. Semaglutide has a half-life of approximately one week, meaning consistent weekly dosing maintains stable therapeutic levels [2]. Patients who frequently miss doses or delay injections experience fluctuating drug concentrations that reduce both efficacy and tolerability. Concurrent lifestyle modifications—particularly a 500-750 kcal daily energy deficit and 150 minutes weekly moderate-intensity activity—significantly enhance weight loss at every dose level compared to medication alone [4].

Genetic factors affecting GLP-1 receptor sensitivity and metabolic rate influence individual dose requirements, though these cannot be predicted before starting treatment. Your UK prescriber monitors your response through regular weight measurements and adjusts the titration pace accordingly. At Cured Pharmacy, we provide ongoing clinical support throughout your treatment journey, with our registered team available on (+44) 116 4646009 to discuss any concerns about dosing or side effects.

Medical Conditions That May Affect Wegovy Dosing

Patients with gastroparesis or severe gastrointestinal disorders may experience exaggerated side effects even at low Wegovy doses, as semaglutide delays gastric emptying [3]. Those with thyroid disease require careful monitoring, as GLP-1 receptor agonists can affect thyroid function in susceptible individuals. Your online consultation at Cured Pharmacy includes comprehensive screening for these conditions, ensuring the prescriber can make informed decisions about whether Wegovy is appropriate and which titration schedule best suits your medical history.

Getting Started with Wegovy at Cured Pharmacy

Starting your Wegovy treatment through Cured Pharmacy combines clinical expertise with transparent pricing and convenience. Our online consultation takes under 3 minutes and covers your medical history, current medications, weight loss goals, and any contraindications. A UK-registered prescriber reviews your assessment within hours, and if Wegovy is clinically appropriate, we dispense genuine UK-licensed medication directly to your door in discreet packaging.

Wegovy is available from £79.00 at Cured Pharmacy, with prices displayed upfront before your consultation—no hidden fees or surprise charges. We supply the complete titration kit containing all dose strengths you'll need for the escalation schedule, eliminating the need for multiple prescriptions as you progress through treatment. Each pen is pre-filled for single use, and we provide comprehensive injection technique guidance with your first order.

All Wegovy prescriptions require ongoing clinical oversight. Your prescriber will schedule follow-up assessments at 12-week intervals to monitor weight loss progress, side effects, and any dose adjustments needed. As a fully registered UK pharmacy (GPhC 9012511) under superintendent pharmacist Tarun Kumar (GPhC 2233073), we maintain the same clinical standards as traditional high-street pharmacies whilst offering the convenience of online access and competitive pricing. Start your free consultation today to determine if Wegovy is right for your weight management goals.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/13799
4. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy (semaglutide) is a prescription-only medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities, alongside a reduced-calorie diet and increased physical activity. Individual results may vary, and weight loss outcomes depend on adherence to the prescribed regimen and lifestyle modifications. Common side effects include nausea, diarrhoea, vomiting, constipation, and abdominal pain. Serious risks include pancreatitis, gallbladder disease, and thyroid tumours (observed in animal studies). Wegovy is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This information does not replace professional medical advice from your prescriber or GP.